Locus Biosciences
Morrisville
About Locus Biosciences
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment more quickly, resulting in a better medical outcome.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $118.7M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2022)
- Website: locus-bio.com
- Phone: (919) 495-4510
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/locus-biosciences-94371 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.